AMENDMENTS TO THE CLAIMS

In the claims

1-18. (canceled)

19. (currently amended) A non-viral complex for delivering a nucleic acid to a cell, comprising:
    a) a ~~polymeric~~ membrane-active compound capable of disrupting membranes covalently attached to an interaction modifier via ~~containing~~ a labile bond;
    b) a polymer; and,
    c) the nucleic acid.

20. (currently amended) A non-viral complex for transfecting a cell, comprising:
    a) a ~~polymeric~~ polymer containing a plurality of membrane-active compounds capable of disrupting membranes wherein the membrane active compounds are attached to the polymer via ~~containing a~~ labile bonds; (see page 24)
    b) a polycation polymer containing a labile bond; and,
    c) the nucleic acid.

21. (original) The complex of claim 19 wherein the polymer contains a labile linkage.

22. (currently amended) The complex of claim 20 wherein the polycation polymer is attached to the membrane-active compound by the labile linkage.

23. (original) The complex of claim 19 wherein the polymer inhibits the polymeric membrane-active compound.

24. (currently amended) The ~~process~~ complex of claim 19 or 20 ~~and 21~~ wherein the labile linkage is selected from the group consisting of pH-labile, ~~very pH-labile and extremely pH-labile~~, a pH-labile bond with a half-life of less than 45 minutes at pH 5, a pH labile bond with a half-life of less than 15 minutes at pH 5.

25. (currently amended) The ~~process~~ complex of claim 19 or 20 ~~and 21~~ wherein the labile linkage is selected from the group consisting of disulfide, acetal, ketal, enol ether, enol ester, amide, imine, imminium, enamine, silyl ether, silazane, and silyl enol ether bonds.

26. (currently amended) The ~~process~~ complex of claim 19 or 20 ~~and 21~~ wherein the labile linkage is selected from the group consisting of diols, diazo, ester, sulfone, and silicon-carbon bonds.

27-35. (canceled)